Allspring Global Investments’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Allspring Global Investments’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-3,827	Closed	-$20K	–	2435
2023 Q4	$20K	Sell	3,827 -187,808	-98%	-$1.85M	﹤0.01%	1966
2023 Q3	$3.02M	Buy	191,635 +20,204	+12%	+$363K	0.01%	1090
2023 Q2	$3.33M	Sell	171,431 -50,999	-23%	-$1.21M	0.01%	1096
2023 Q1	$6.31M	Buy	222,430 +71,802	+48%	+$2.13M	0.01%	935
2022 Q4	$4.4M	Buy	150,628 +62,456	+71%	+$1.99M	0.01%	1010
2022 Q3	$2.33M	Sell	88,172 -119,997	-58%	-$4.4M	﹤0.01%	1194
2022 Q2	$9.25M	Sell	208,169 -43,810	-17%	-$2.01M	0.02%	796
2022 Q1	$12.5M	Sell	251,979 -23,326	-8%	-$1.12M	0.02%	812
2021 Q4	$14M	Buy	+275,305	New	+$14.3M	0.02%	823

Other funds holding EGRX

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.82% 1-Year Est. Return

Allspring Global Investments's EGRX Position: Q1 2024 in Review

Allspring Global Investments sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2024, closing a stake of 3,827 shares — an estimated $20K sold.

Allspring Global Investments first reported a position in EGRX in Q4 2021 and held it in 9 quarters. The position peaked at $14M in Q4 2021. 91 funds tracked by Wall St. Rank hold EGRX as of Q1 2024.

Allspring Global Investments reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
Allspring Global Investments sold 3,827 Eagle Pharmaceuticals, Inc. shares in Q1 2024, an estimated $20K.
Allspring Global Investments first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2021 and held it in 9 quarters.
Allspring Global Investments's Eagle Pharmaceuticals, Inc. position peaked at $14M in Q4 2021.
91 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2024.

Based on Allspring Global Investments's 13F filing for Q1 2024, filed 18 Apr 2024.